engleski

Lethal toxicity following standard dose of 5-FU in patients carrying DPYD c.1905+1G>A mutation

Dihydropyrimidine dehydrogenase (DPD) is the key enzyme in the detoxification of 5-fluorouracil (5-FU). Patients with DPD deficiency are at increased risk of severe toxicity from 5-FU. UGT1A1 is important for the irinotecan pharmacokinetic. DPYD c.1905+1AA mutation is known to result in DPD deficiency which is the cause of severe adverse and sometimes lethal reactions to 5-FU. UGT1A1 is also important for the irinotecan pharmacokinetic. The genotyping of cancer patients for DPYD and irinotecan gene variants prior to administration of 5-FU would be desirable for identification of increased risk of severe toxicity.

DPYD; 5-FU; toxicity

nije evidentirano